U.S. court upholds Amgen patents on arthritis drug Enbrel

A U.S. judge on Friday said patents relating to the Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version.